VivoSeq
Metabolic & Endocrine

Mixed Dyslipidemia

0

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Mixed Dyslipidemia is an early-stage landscape with 0 programs across 4 companies. The most active players are Arrowhead Pharmaceuticals, Shanghai Argo Biopharmaceutical Co., Ltd., IlDong Pharmaceutical Co Ltd.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals

0 programs

PreclinicalS

Shanghai Argo Biopharmaceutical Co., Ltd.

0 programs

PreclinicalIlDong Pharmaceutical Co Ltd logo

IlDong Pharmaceutical Co Ltd

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

8

clinical trials

Completed7 · 88%
Active, not recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

A Study in Patients With Mixed Dyslipidemia
Active, not recruiting·SShanghai Argo Biopharmaceutical Co., Ltd.·Phase 2·NCT06497127·145 enrolled
Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
Completed·Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals·Phase 2·NCT04998201·353 enrolled
Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia
Completed·IlDong Pharmaceutical Co Ltd logoIlDong Pharmaceutical Co Ltd·Phase 3·NCT02262143·362 enrolled
A Study of LY3561774 in Participants With Mixed Dyslipidemia
Completed·Eli Lilly logoEli Lilly·Phase 2·NCT05256654·205 enrolled
An Evaluation of Simvastatin Plus Omacor Compared to Simvastatin Plus Placebo in Subjects With Mixed Dyslipidemia
Completed·PProvident Clinical Research·N/A·NCT00487591·40 enrolled
A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia
Completed·AAbbott·Phase 3·NCT00491530·310 enrolled
Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
Completed·Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals·Phase 2·NCT04832971·204 enrolled
Bezafibrate Plus Berberine in Mixed Dyslipidemia
Completed·UUniversity of Guadalajara·Phase 3·NCT02548832·36 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)